Groupe d'Etude en Oncologie du Quebec

Titre	A Phase 3, Open-Label, Randomized Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Patients With Previously Untreated Chronic Lymphocytic Leukemia
Protocole ID	BGB-11417-301
ClinicalTrials.gov ID	NCT06073821
Type(s) de cancer	Leucémie lymphoïde chronique (LLC)
Phase	Phase III
Type étude	Clinique
Médicament	Sonrotoclax + zanubrutinib comparé à vénétoclax + obinutuzumab
Institution	CIUSSS DE L'ESTRIE – CENTRE HOSP. UNIV. DE SHERBROOKE HOPITAL FLEURIMONT 3001 12e Avenue Nord, Sherbrooke, QC, J1H 5N4
Ville	Sherbrooke
Investigateur(trice) principal(e)	Dre Dominique Toupin
Coordonnateur(trice)	Anick Champoux 819-346-1110 poste 12811
Statut	Fermé
Critètes d'éligibilité	Treatment-naïve (TN) adults with confirmed diagnosis of CLL which requires treatment Eastern Cooperative Oncology Group (ECOG) score 0, 1, or 2 Measurable disease by Computer Tomography/Magnetic Resonance Imaging Adequate liver function as indicated by aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x the institutional upper limits of normal (ULNs) value; serum total bilirubin < 3.0 x ULN Adequate renal function as defined as creatinine clearance ≥ 50 milliliters per minute
Critètes d'exclusion	Previous systemic treatment for CLL Known prolymphocytic leukemia or history of, or currently suspected, Richter's transformation Known central nervous system involvement History of confirmed progressive multifocal leukoencephalopathy (PML) Uncontrolled hypertension

Groupe d'étude en oncologie du Québec